Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
AMPA receptor
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Positive allosteric modulators== {{Main|AMPA receptor positive allosteric modulator}} {{div col|colwidth=22em}} * [[Aniracetam]] * [[Cyclothiazide]] * [[CX-516]] * [[CX-546]] * [[CX-614]] * [[Osavampator]] (TAK-653) * [[CX-717]] * [[Farampator]] (CX-691, ORG-24448) * [[IDRA-21]] * [[LY-404187]] * [[LY-503430]]<ref name="pmid12730350">{{cite journal | vauthors = Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, O'Neill MJ | display-authors = 6 | title = LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 306 | issue = 2 | pages = 752β62 | date = August 2003 | pmid = 12730350 | doi = 10.1124/jpet.103.049445 | s2cid = 86751458 }}</ref><ref name="pmid15180479">{{cite journal | vauthors = O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES | title = AMPA receptor potentiators for the treatment of CNS disorders | journal = Current Drug Targets. CNS and Neurological Disorders | volume = 3 | issue = 3 | pages = 181β94 | date = June 2004 | pmid = 15180479 | doi = 10.2174/1568007043337508 }}</ref> * [[Mibampator]] (LY-451395) * [[ORG-26576]] * [[Oxiracetam]] * [[PEPA (drug)|PEPA]] * [[Pesampator]] (BIIB-104) * [[Piracetam]] * [[Pramiracetam]] * [[Traneurocin]] (NA-831) * [[Tulrampator]] (S-47445, CX-1632) {{div col end}}
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)